COLL today
$24.95+$0.14 (+0.56%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourSymmetric Triangle
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns down below $23.25
Key levels
Resistance$26.39
Resistance$25.44
Support$24.50
Support$23.25
Latest news & SEC filings
AnalystPiper Sandler keeps Neutral rating on Collegium Pharmaceutical, cuts target to $28
AnalystNeedham keeps Buy rating on Collegium Pharmaceutical, cuts price target
All COLL news →About Collegium Pharmaceutical
Collegium Pharmaceutical is a biopharmaceutical company that develops, licenses, and sells prescription medicines in the United States. Its products treat attention deficit hyperactivity disorder and pain, including an abuse-deterrent extended-release opioid, a buccal film, oral tapentadol tablets, and a therapy for opioid-induced constipation. The company sells mainly to wholesalers, which supply retail pharmacies, health plans, and public agencies. It uses separate sales teams for its pain and ADHD portfolios.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
COLLEGIUM PHARMACEUTICAL, INC (COLL)
What Is the Price Target for COLL?
SEPT Low Target
$43.00
SEPT Mid Target
$46.50
SEPT High Target
$50.00
Analyst Consensus
$46.50
Is COLL a Buy or Sell Right Now?
Thesis
- •Revenue growing 23.6% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for COLL.
Start Free Trial →Is COLL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$57.52
54
Moat Score
NARROW
7/9
Piotroski Score
1.3
Altman Z-Score
What Is Smart Money Doing with COLL?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SANTINI GINO | director | Buy | 8,700 | $143K | Jun 8, 2026 |
| Freund John Gordon | director | Sale | 20 | $681.00 | May 18, 2026 |
| Freund John Gordon | director | Buy | 8,700 | $143K | May 15, 2026 |
| Freund John Gordon | director | Sale | 4,127 | $143K | May 15, 2026 |
| Glancy Donovan Michael | director | Buy | 17,482 | - | May 14, 2026 |
| Balice-Gordon Rita J. | director | Buy | 8,741 | - | May 14, 2026 |
| Paya Carlos V | director | Buy | 8,741 | - | May 14, 2026 |
| Lurker Nancy | director | Buy | 8,741 | - | May 14, 2026 |
| Freund John Gordon | director | Buy | 8,741 | - | May 14, 2026 |
| SANTINI GINO | director | Buy | 8,741 | - | May 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →COLL Growth Story
Revenue YoY
23.6%
3yr Revenue CAGR
18.9%
EPS Growth YoY
-6.99%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for COLL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for COLL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:24 | $24.95 | 1,515 | $$38K | BUY |
| 20:55:00 | $24.96 | 1,100 | $$27K | BUY |
| 19:49:33 | $24.86 | 1,000 | $$25K | BUY |
| 19:48:01 | $24.86 | 1,000 | $$25K | BUY |
| 19:44:53 | $24.89 | 1,000 | $$25K | BUY |
5 dark pool trades shown · $$140K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for COLLEGIUM PHARMACEUTICAL, INC (COLL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →COLL — frequently asked questions
What is COLL stock price today?
COLLEGIUM PHARMACEUTICAL, INC (COLL) is at $24.95, up 0.56% (+$0.14) at the Nov 12, 2026 close.
Why is COLL stock moving today?
Latest COLL news — Nov 6, 2026: Piper Sandler keeps Neutral rating on Collegium Pharmaceutical, cuts target to $28 · Nov 5, 2026: Needham keeps Buy rating on Collegium Pharmaceutical, cuts price target
Why did COLL stock move on Nov 5, 2026?
Collegium Pharmaceutical reported Q3 2026 results, posting adjusted earnings of $1.96 per share that beat the $1.86 consensus, while revenue of $216.339 million came in slightly below the $217.276 million consensus. The company also held its Q3 2026 earnings call and filed a Form 8-K disclosing a major company event.
What is the COLL price target?
The average analyst price target for COLL is $46.50, ranging from $43 to $50, based on 6 analysts. Latest: Needham maintains on Nov 5, 2026.
What do analysts rate COLL?
Analyst ratings for COLL: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did COLL beat earnings?
COLL last reported on Aug 6, 2026: EPS $1.92 vs $1.72 expected — a beat of 11.6%.
What is COLL's P/E ratio?
COLL trades at a P/E of 18.8 vs a Healthcare average of 18.5.
Does COLL pay a dividend?
COLL does not currently pay a dividend.
What are COLL support and resistance levels?
Support: $24.50, $23.25, $22.15. Resistance: $25.44, $26.39, $28.34.
What are insiders doing with COLL?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on COLL?
Nov 6, 2026: Piper Sandler keeps Neutral rating on Collegium Pharmaceutical, cuts target to $28 · Nov 5, 2026: Needham keeps Buy rating on Collegium Pharmaceutical, cuts price target